HC Wainwright Has Positive Outlook for JSPR Q3 Earnings

Jasper Therapeutics, Inc. (NASDAQ:JSPR) – Equities research analysts at HC Wainwright increased their Q3 2026 EPS estimates for Jasper Therapeutics in a note issued to investors on Monday, August 17th. HC Wainwright analyst E. Bodnar now anticipates that the company will post earnings per share of $0.16 for the quarter, up from their previous estimate of ($0.47). HC Wainwright currently has a “Buy” rating on the stock. The consensus estimate for Jasper Therapeutics’ current full-year earnings is ($1.47) per share. HC Wainwright also issued estimates for Jasper Therapeutics’ Q4 2026 earnings at ($0.42) EPS, FY2026 earnings at ($0.89) EPS, FY2027 earnings at ($1.31) EPS, FY2028 earnings at ($1.62) EPS, FY2029 earnings at ($2.23) EPS and FY2030 earnings at ($2.76) EPS.

Jasper Therapeutics (NASDAQ:JSPR) last released its quarterly earnings data on Friday, August 14th. The company reported ($0.10) earnings per share for the quarter, beating the consensus estimate of ($0.27) by $0.17.

Several other analysts have also issued reports on JSPR. Wall Street Zen lowered Jasper Therapeutics from a “hold” rating to a “sell” rating in a report on Saturday. Royal Bank Of Canada set a $3.00 target price on Jasper Therapeutics and gave the company a “sector perform” rating in a research note on Friday, May 15th. TD Cowen downgraded Jasper Therapeutics from a “buy” rating to a “hold” rating in a research note on Friday, May 15th. Piper Sandler started coverage on Jasper Therapeutics in a report on Wednesday, August 12th. They set an “overweight” rating and a $2.00 price target for the company. Finally, Weiss Ratings reissued a “sell (e+)” rating on shares of Jasper Therapeutics in a research note on Friday, July 17th. Six analysts have rated the stock with a Buy rating, three have assigned a Hold rating and one has assigned a Sell rating to the stock. Based on data from MarketBeat.com, Jasper Therapeutics has an average rating of “Moderate Buy” and a consensus price target of $8.17.

Jasper Therapeutics Stock Down 10.9%

Shares of NASDAQ:JSPR opened at $0.75 on Wednesday. The firm has a fifty day moving average of $0.61 and a two-hundred day moving average of $0.89. Jasper Therapeutics has a 12-month low of $0.32 and a 12-month high of $3.05. The firm has a market capitalization of $21.00 million, a P/E ratio of -0.47 and a beta of 3.02.

Hedge Funds Weigh In On Jasper Therapeutics

Institutional investors have recently modified their holdings of the company. Knott David M Jr increased its position in Jasper Therapeutics by 5.8% during the fourth quarter. Knott David M Jr now owns 181,389 shares of the company’s stock worth $332,000 after acquiring an additional 10,000 shares during the period. Acadian Asset Management LLC acquired a new stake in Jasper Therapeutics in the 1st quarter worth $46,000. Engineers Gate Manager LP acquired a new stake in Jasper Therapeutics in the 2nd quarter worth $78,000. Renaissance Technologies LLC increased its holdings in shares of Jasper Therapeutics by 9.0% during the 4th quarter. Renaissance Technologies LLC now owns 227,183 shares of the company’s stock worth $416,000 after purchasing an additional 18,683 shares during the period. Finally, Panagora Asset Management Inc. bought a new position in shares of Jasper Therapeutics during the 4th quarter worth about $35,000. Institutional investors own 79.85% of the company’s stock.

About Jasper Therapeutics

Jasper Therapeutics, Inc (NASDAQ: JSPR) is a clinical-stage biopharmaceutical company focused on translating advances in immunobiology into therapies for serious and rare diseases with unmet medical needs. The company’s research and development efforts center on engineered biologics and cell-based approaches designed to address complications in hematologic conditions and improve outcomes in transplant medicine.

Central to Jasper’s pipeline is JSP191, a monoclonal antibody targeting the CD117 receptor, which is being evaluated to enhance donor hematopoietic stem cell engraftment in patients undergoing stem cell transplantation.